Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
https://european-biotechnology.com/wp-content/uploads/2024/06/EBC_c_CDC.png400704Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-05-26 08:51:002024-07-08 11:08:15Hornet Therapeutics reports first data of EBV-triggered disease blocker